Overall, these experiments uncovered two fundamentally different effects of drugs on cancer cell populations: the EGFR (T790M) inhibitor alone kills cells independently of their clonal properties, while in the presence of the DYRK1B inhibitor it kills cells selectively, depending on their clonal origin. The gene discussed is EGFR; the disease is cancer.